Inhibition of sars-COV-2 infection with a pan-coronavirus anti-viral peptide
Ended Project Grant Awarded Last action
- Award ID
- R43AI157521
- Recipient
-
Sapience Therapeutics, Inc. UEI ERRLJEYAUMC8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,131,832
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Funding
-
- $831,971.59 Federal
- $299,860.00 Non-federal
- Place of performance
- New York, USA
Award details come from USAspending.gov.
Description
- Abstract
- The covid-19 pandemic, caused by the sars-COV-2 virus, is a serious threat to global public health, necessitating the rapid development of safe and effective medical countermeasures. Sars-COV-2 pathogenicity requires a series of protein-protein interactions (PPI) involving the virus' s protein that leads to virus attachment and fusion. Initially, the receptor binding domain (RBD) on the s protein S1 subunit binds to ACE2 receptors on the host cell. This triggers a conformational change in the s protein S2 subunit, driving the viral heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains of S2 to form a six-helical bundle (6-HB), enabling the viral envelope to be brought in close proximity to the host membrane, thus promoting viral fusion. Peptides have emerged recently as a therapeutic class capable of targeting and disrupting PPI with high affinity and specificity. We hypothesize antagonism of the virus s protein with a peptide therapeutic will provide an effective anti-viral strategy for sars-COV-2 infection, and potentially a pan-coronavirus intervention. We propose a plan to select a lead candidate peptide antagonist based upon target binding and viral neutralization in vitro, with consideration of escape mutants, and attenuation of virus load and shedding in a ferret challenge model in vivo. Successful completion of this program will support advancement of the lead candidate peptide to IND-enabling studies, and provide the rationale for submission of a phase II sbir proposal to evaluate inhalation delivery for severe respiratory disease.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$288,178 | $0 | |
| Amendment | -$55,926 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $288,178 | $0 | |
| Amendment | $288,178 | $0 | |
| Amendment | $299,860 | $0 | |
| Original award | $299,860 | $299,860 |
Quick answers
Who received award R43AI157521?
R43AI157521 was awarded to Sapience Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 4, 2021.
How much is award R43AI157521 worth?
$1,131,832 has been obligated on R43AI157521: $831,972 in federal funding and $299,860 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award